Multiplex immunohistochemistry/immunofluorescence is superior to tumor mutational burden and PD‐L1 immunohistochemistry for predicting response to anti‐PD‐1/PD‐L1 immunotherapy

Bibliographic Details
Main Author: Weixian Hu
Format: Article
Language:English
Published: Wiley 2020-01-01
Series:Thoracic Cancer
Online Access:https://doi.org/10.1111/1759-7714.13233